Vadim S. Gadzhiagaev

Vadim S. Gadzhiagaev

Auto-generated profile, based on publicly available information

Vadim S. Gadzhiagaev

Moscow Regional Research and Clinical Institute (“MONIKI”)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AKAnton Konovalov
Anton Konovalov
VGVadim Gadzhiagaev
Vadim Gadzhiagaev
FGFyodor Grebenev
Fyodor Grebenev
DSDmitry Stavtsev
Dmitry Stavtsev
GPGennadii Piavchenko
Gennadii Piavchenko
SEShalva Eliava
Shalva Eliava

14 February 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AKAnton Konovalov
Anton Konovalov
VGVadim Gadzhiagaev
Vadim Gadzhiagaev
EVEvgeniy Vinogradov
Evgeniy Vinogradov
NNNikita Nikitin
Nikita Nikitin
SEShalva Eliava
Shalva Eliava
NKNikolay Konovalov
Nikolay Konovalov

14 June 2022 in World Neurosurgery
Verified
Journal Article
Closed access
VGVadim S. Gadzhiagaev
Vadim S. Gadzhiagaev
OSOleg D. Shekhtman
Oleg D. Shekhtman
AKAnton N. Konovalov
Anton N. Konovalov
SEShalva S. Eliava
Shalva S. Eliava
YPYuri V. Pilipenko
Yuri V. Pilipenko
YSYulia V. Strunina
Yulia V. Strunina

13 October 2023 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
NLNikolay Lasunin
Nikolay Lasunin
VCVasiliy Cherekaev
Vasiliy Cherekaev
AAAbdulla Abdullaev
Abdulla Abdullaev
VGVadim Gadzhiagaev
Vadim Gadzhiagaev
GDGleb Danilov
Gleb Danilov
DODmitriy Okishev
Dmitriy Okishev

8 November 2021 in Surgical Neurology International
Verified
Journal Article
Open access
AKAnton Konovalov
Anton Konovalov
OSOleg Sharipov
Oleg Sharipov
OSOleg Shekhtman
Oleg Shekhtman
VGVadim Gadzhiagaev
Vadim Gadzhiagaev
PKPavel Kalinin
Pavel Kalinin
Background: Central nervous system (CNS) aspergillosis is more often met in patients with expressed immune suppression. Still, in 50% of cases of meningitis caused by Aspergillus spp., it is observed in patients without expressed immune suppression. The prognosis of CNS aspergillosis is unfavorable with the general rate of lethality around 70%. Case Description: Clinical case of a 58-year-old man who developed an Aspergillus abscess in the chiasmosellar region and an associated mycotic aneurysm of the right middle cerebral artery (MCA) and intracerebral hemorrhage. Microsurgical clipping of the fusiform-ectatic aneurysm of the right MCA in the conditions of rupture was performed. An extra-intracranial micro anastomosis was formed on the right. An open biopsy of the neoplasm in the chiasmosellar region was made. The neoplasm was yellow and destroyed the bone plate of the skull base. Biopsy results: Mycotic lesion (aspergillosis). The analysis of surgical treatment for mycotic aneurysms in the acute period of hemorrhage in patients with aspergillosis revealed a high rate of lethality. The issue of the feasibility and effectiveness of complicated revascularization interventions in the patients with hemorrhage and aspergillosis remains unsolved. Conclusion: The lack of generally accepted tactics of the treatment of this pathology requires further studies and systemic analysis. A high risk of the lethal outcome in patients with invasive mycotic infection and rupture of mycotic aneurysm highlight the importance of timely diagnostics and the beginning of antimycotic therapy. WThe issue of the evaluation of the revascularization methods effectiveness in patients after surgical treatment of a mycotic aneurysm associated with cerebral aspergillosis remains poor.

18 June 2024 in Cureus
Verified
Journal Article
Open access
PDF file
AKAnton Konovalov
Anton Konovalov
FGFyodor Grebenev
Fyodor Grebenev
AAAnton Artemyev
Anton Artemyev
VGVadim Gadzhiagaev
Vadim Gadzhiagaev
YPYuri Pilipenko
Yuri Pilipenko
BCBipin Chaurasia
Bipin Chaurasia
Background: Patients with intracranial aneurysms often have comorbidities that require them to take acetylsalicylic acid (ASA). In recent years, many patients with aneurysms have been prescribed ASA to prevent aneurysm enlargement. ASA is also prescribed to patients with intracranial aneurysms in preparation for surgical revascularization. Methods: From 2016 to 2021, 64 patients underwent microsurgical aneurysm clipping without revascularization, and an additional 20 patients underwent extracranial to intracranial (EC-IC) bypass. The following parameters were analysed: the frequency of hemorrhagic complications, the blood loss volume, the duration of surgery and inpatient treatment, the change in hemoglobin level (Hb), hematocrit (Ht), erythrocytes, and clinical outcomes according to the modified Rankin scale (mRS). Results: At the time of surgery, laboratory-confirmed effect of the ASA was registered in 22 patients (main group). In 42 patients, the ASA was not functional on assay (control group). Hemorrhagic complications were noted in two patients in the ASA group. In both cases, the hemorrhagic component did not exceed 15 ml in volume and did not require additional surgical interventions. Statistical analysis showed no significant differences in hemorrhagic postoperative complications. Conclusion: Taking low doses of acetylsalicylic acid during planned microsurgical clipping of cerebral aneurysms does not affect intraoperative blood loss volume, risk of postoperative hemorrhagic complications, length of stay in the hospital, or functional outcomes.